Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Enzolytics Inc ENZC

Healthcare Biotechnology
Enzolytics, Inc. is a drug development company. The Company is engaged in the commercialization of its proteins and monoclonal antibodies for the treatment of debilitating infectious diseases. Its patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF) for the treatment of human immunodeficiency virus/ acquired... see more

Recent & Breaking News (PINL:ENZC)

Enzolytics Inc. Announces Dismissal of The Dimitar Savov Lawsuit in Nevada

Accesswire 2 days ago

Update on Formulation of New Business Strategy

Accesswire 13 days ago

ENZOLYTICS, INC. SHAREHOLDERS HOLD SPECIAL MEETING AND ELECT NEW BOARD

PR Newswire March 25, 2024

Enzolytics, Inc. Announces Partnership With the Khalpey AI Lab To Forge the Future of Multi-Organ Remodeling and Rejuvenation With a Strategic Focus on Longevity

Accesswire January 16, 2024

Enzolytics, Inc. Files Amended December 31, 2022 OTC Report with Audited Financials and Unaudited September 30, 2023 Quarterly Disclosure

Accesswire November 20, 2023

Enzolytics Announces the Signing of the Business Combination Agreement with Sagaliam Acquisition Corp (SAGA)

Accesswire September 18, 2023

SAGALIAM ACQUISITION CORP. ANNOUNCES EXECUTION OF DEFINITIVE BUSINESS COMBINATION AGREEMENT AND RECEIPT OF NASDAQ LISTING DELINQUENCY LETTER

GlobeNewswire September 15, 2023

Patient Population for the Clinical Trials of ITV-1 has been Established by the European Medicines Agency ("EMA")

Accesswire September 6, 2023

Biogenysis, Inc. Announces Partnering with Khalpey AI Lab and Contenta, Ltd. to Incorporate AI in Microbiome Analysis to Identify Biomarkers for Use in Accurately Predicting Alzheimer's Disease Onset and Prevention.

Accesswire September 5, 2023

Biogenysis' International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.

Accesswire August 24, 2023

Virogentics, Inc. Receives Permit for Export to Africa of the ITV-1 Immunotherapy Solidifying the Scheduled Administration of the Treatment

Accesswire August 8, 2023

Virogentics, Inc. Provides Update on African Project, European Medicine Agency Application and Clinical Trials for Application for Type 2 Diabetes

Accesswire August 4, 2023

CORRECTION FROM SOURCE: Virogentics Announces Approval of Final Protocol from the Dept for HIV and AIDS, Ministry of Health of the DRC

Accesswire July 24, 2023

Virogentics, Inc to Introduce a Dietary Supplement Offers Additional Information on ITV-1 and Diabetic Clinical Trials

Accesswire July 24, 2023

Biogenysis Inc. Announces a Collaboration with Khalpey AI Lab in using Artificial Intelligence (AI) for Unveiling Potential Biomarkers and Predicting the Onset or Prevention of Alzheimer's Disease.

Accesswire July 21, 2023

Enzolytics Inc. Files Supplemental Information Report on the Sale of Biogenysis, Inc. and Virogentics, Inc to Sagaliam Acquisition Corp.

Accesswire July 11, 2023

Virogentics, Inc to Introduce a Dietary Supplement Offers Additional Information on ITV-1 And Diabetic Clinical Trials

Accesswire July 6, 2023

Enzolytics, Inc. Reports Amendment to Non-Binding Term Sheet with the Special Purpose Acquisition Company Sagaliam Acquisition Corp.

Accesswire June 29, 2023

Enzolytics Offers Update on Virogentics, Inc ITV-1 African Project

Accesswire June 26, 2023

Enzolytics Offers Update on Virogentics and Sale Transaction, Clinical Trials Progress on European Medicine Agency (EMA) Permitting and Arican ITV-1 Project

Accesswire June 5, 2023